Iterum Therapeutics

101 articles with Iterum Therapeutics

• Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

  3/12/2021

  - -NDA for Oral Sulopenem has PDUFA date of July 25, 2021 --   - -Cash Runway into First Half of 2023 — --Company to host conference call today at 8:30amET--

• Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021

  3/5/2021

  Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2020 financial results

• Iterum Therapeutics to Present in Upcoming Investor Conferences

  2/19/2021

  Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, will provide a company overview and business update at the following upcoming investor conferences:

• Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares

  2/10/2021

  Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the underwriter of its previously announced underwritten public offering of ordinary shares,

• Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules

  2/10/2021

  Iterum Therapeutics plc announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 17,500,000 of its ordinary shares at a purchase price of $2.00 per ordinary share in a registered direct offering priced at-the-market under Nasdaq rules.

• Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million

  2/4/2021

  Iterum Therapeutics plc announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 34,782,609 ordinary shares at a public offering price of $1.15 per share, less underwriting discounts and commissions.

• Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares

  2/3/2021

  Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC

• Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch

  2/1/2021

  Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced it has engaged EVERSANA™,

• Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem

  1/25/2021

  Iterum Therapeutics plc today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in patients with a quinolone non-susceptible pathogen.

• Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference

  1/6/2021

  Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that management will participate in the H.C. Wainwright BioConnect Conference being held virtually from January 11-14, 2021. Corey Fishman, Chief Executive Offic

• Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors

  12/23/2020

  Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Dr. Michael Dunne has resigned from his role as Chief Scientific Officer of the Company, effective December 21, 2020.

• Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketTrading on Nasdaq Capital Market is expected to begin on December 23, 2020

  12/21/2020

  Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that on December 18, 2020, the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) approved the Company's request to transfer its listing

• Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable Written Opinion of the International Search Authority

  12/7/2020

  Bilayer tablet patent application could provide U.S. patent coverage for Iterum’s commercial formulation through 2039, if granted

• Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

  11/30/2020

  Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sulopenem etzadroxil/probenecid (

• Iterum Therapeutics Reports Third Quarter 2020 Financial ResultsNDA Filing Expected Q4 2020

  11/16/2020

  Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, reported financial results for the third quarter ended September 30, 2020.

• Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering - Oct 23, 2020

  10/23/2020

  Iterum Therapeutics plc announced the pricing of a public offering of 26,923,076 ordinary shares, together with warrants to purchase up to 20,192,307 ordinary shares at a combined effective price to the public of $0.65 per ordinary share and associated warrant.

• UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

  10/19/2020

  Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

• Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

  10/19/2020

  Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it will have two data presentations at the Infectious Disease Society of America (IDSA) IDWeek™ 2020 taking place virtually from October 21 - 25, 2020. Th

• 

  BioSpace Global Roundup, Oct. 1

  10/1/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and business practices.

• Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem for Treatment of Uncomplicated Urinary Tract Infections

  9/30/2020

  Iterum Therapeutics plc announced that, based on discussions at a pre-NDA meeting with the U.S. Food and Drug Administration, it plans to proceed with an NDA submission for sulopenem etzadroxil/probenecid, a bilayer tablet, for the treatment of uncomplicated urinary tract infections in patients with a quinolone-resistant pathogen.